HUAWEI
21.11.2022 12:24:40 CET | Business Wire | Press release
Huawei’s ability to build more energy-efficient data centers could be an example to others as decarbonization of the construction sector picks up worldwide, according to a company spokesperson.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005364/en/
Andrew Williamson, Vice President of Government Affairs and Economic Advisor, Huawei speaks at the panel. (Photo: Business Wire)
Andrew Williamson, Vice President of Government Affairs and Economic Advisor at Huawei, said “smart” digital infrastructure and buildings are becoming especially common in China’s Guangdong–Hong Kong–Macao Greater Bay Area (GBA).
“The modularization of data center facilities creates new possibilities for fast construction and with a lower carbon footprint,” said Williamson, who stressed that construction times can be reduced to six months from 18 months, thanks to steel prefabricated design.
“This solution uses much less concrete than conventional buildings, and carbon emissions in the construction phase could be offset by more than 90 percent,” he said.
Williamson made the remarks as he addressed a session organized by the Global Alliance for Buildings and Construction (GlobalABC) and German Energy Agency at the Buildings Pavilion during the ongoing 27th Conference of the Parties, or COP27, in Sharm El-Sheikh, Egypt. The session also included speakers from the German Federal Ministry for Economic Affairs and Climate Action (BMWK), the Chinese Academy of Building Research, the World Resources Institute, ICLEI East Asia, Shenzhen Institute of Building Research and JA Solar.
“The process itself is really important to get collaboration in motion in the decarbonization of the buildings sector. Essentially it is about bringing the different actors together, getting them to talk to each other and agree on a shared vision and some targets, and to agree on the actions that need to be implemented to transform the sector,” said Jonathan Duwyn, Head of Buildings and Construction Portfolio at the United Nations Environment Programme.
In terms of building green and eco-friendly campuses, Huawei has adopted rooftop photovoltaics (PVs) for many of its own facilities, including the Huawei Dongguan Southern Factory. It has also consistently increased the use of electricity from renewable energy sources, which rose by 42.3 percent to 300 million kWh in 2021.
In its headquarters in Shenzhen and Dongguan of China’s GBA area, Huawei’s campuses are both fully powered by clean energy. Elsewhere in the country, the Chengdu Research Center was the first of its kind for the company to achieve net-zero carbon operations.
The company has also contributed in the concerted global effort to power COP27 with clean solar energy. Together with its partner Infinity Power, Huawei supplied all string inverters to the 6MW solar project that has lit up the COP27 conference center.
The solar plant is expected to generate up to 11,723 MWh of energy a year. That can power 5,000 homes and reduce 4,000-plus tons of CO2 emissions annually.
“The project will also provide green electricity to Sharm el-Sheikh for years to come,” said Williamson.
About Huawei
Founded in 1987, Huawei is a leading global provider of information and communications technology (ICT) infrastructure and smart devices. We have 195,000 employees and we operate in more than 170 countries and regions, serving more than three billion people around the world.
Our vision and mission is to bring digital to every person, home and organization for a fully connected, intelligent world. To this end, we will work towards ubiquitous connectivity and inclusive network access, laying the foundation for an intelligent world; provide diversified computing power where you need it, when you need it, to bring cloud and intelligence to all four corners of the earth; build digital platforms to help all industries and organizations become more agile, efficient, and dynamic; and redefine user experience with AI, making it smarter and more personalized for people in all aspects of their life, whether they're at home, on the go, in the office, having fun, or working out. For more information, please visit Huawei online at www.huawei.com or follow us on:
http://www.linkedin.com/company/Huawei
http://www.twitter.com/Huawei
http://www.facebook.com/Huawei
http://www.youtube.com/Huawei
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005364/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
